Goldberg Law PC, a national shareholder rights litigation firm, announces that it is investigating Meridian Bioscience, Inc. (“Meridian” or the “Company”) (Nasdaq: VIVO) concerning possible violations of federal securities laws.

If you purchased or otherwise acquired Meridian shares and would like more information regarding the investigation, we encourage you to click here, or contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars Suite 1100, Los Angeles, CA 90067, at 800-977-7401, to discuss your rights without cost to you. You can also reach us through the firm’s website at http://www.Goldberglawpc.com, or by email at info@goldberglawpc.com.

On January 25, 2017, Meridian revealed poor first-quarter 2017 fiscal year ("1Q 2017") financial results, changed its formerly issued revenue forecast for the 2017 fiscal year downwards, and mentioned that the Board of Directors reduced the annual indicated dividend rate. John A. Kraeutler, Chief Executive Officer, attributed the negative quarterly results to revenue decreases in Meridian's Americas diagnostic company, Meridian's largest profit driver, across all major product categories, "due to customer buying patterns and general weakness overall."

When this information was released to the public, the value of Meridian stock fell sharply, causing investors harm.

If you have any questions concerning your legal rights, please immediately contact Goldberg Law PC at 800-977-7401, or visit our website at http://www.Goldberglawpc.com, or email us at info@goldberglawpc.com.

Goldberg Law PC represents shareholders around the world and specializes in securities class actions and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.